Premium
Antithrombin reduces monocyte and neutrophil CD11b up regulation in addition to blocking platelet activation during extracorporeal circulation
Author(s) -
Rinder Christine S.,
Rinder Henry M.,
Smith Michael J.,
Fitch Jane C.K.,
Tracey Jayne B.,
Chandler Wayne L.,
Rollins Scott A.,
Smith Brian R.
Publication year - 2006
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1111/j.1537-2995.2006.00861.x
Subject(s) - monocyte , extracorporeal circulation , antithrombin , platelet , neutrophil elastase , integrin alpha m , platelet activation , pharmacology , elastase , medicine , granulocyte , cardiopulmonary bypass , chemistry , heparin , immunology , inflammation , flow cytometry , biochemistry , enzyme
BACKGROUND: Patients undergoing cardiac surgery requiring cardiopulmonary bypass develop a systemic inflammatory reaction. Antithrombin III (AT) has anticoagulant effects but also shows evidence of anti‐inflammatory activity. The aim of this study was to examine whether exogenous AT could reduce white blood cell activation (CD11b up regulation or elastase release), in addition to inhibiting platelet (PLT) activation and fibrin generation, during simulated cardiopulmonary bypass (sCPB), undertaken in the absence of endothelium. STUDY DESIGN AND METHODS: sCPB was carried out with minimally heparinized (2 U/mL) human blood for 90 minutes in controls and with supplementation by low‐dose (1 U/mL) and high‐dose (5 U/mL) AT. RESULTS: High‐dose AT blunted thrombin generation during sCPB (prothrombin fragment 1.2); both doses significantly inhibited thrombin activity (fibrinopeptide A). Complement activation (C3a and C5b‐9) was unaffected by AT. High‐dose AT inhibited PLT activation (P‐selectin expression and P‐selectin–dependent monocyte‐PLT conjugate formation). AT supplementation at the higher dose significantly abrogated monocyte and neutrophil CD11b up regulation and neutrophil elastase release. CONCLUSION: In addition to anticoagulant and anti‐PLT effects, pharmacologic AT doses significantly blunted monocyte and neutrophil CD11b up regulation and neutrophil elastase release during sCPB, independent of endothelial effects. These data provide evidence for the direct anti‐inflammatory activity of AT that has clinical relevance for CPB complications.